Oxygen Biotherapeutics Provides Update On Recent Events And Phase IIb Oxycyte Clinical Trial (Medical News Today)
Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) is providing an update on the status of the Oxycyte Phase IIb protocol that has been submitted to the FDA. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. "We are in the process of submitting a final piece of information requested by the FDA. After that data has been submitted, we will wait to hear back from them.

Lutronic Announces FDA Clearance And Immediate Availability Of Its ECO2, The First Multi-Functional Fractional CO2 ... (Medical News Today)
Lutronic, Inc., one of the world's leading developers and manufacturers of aesthetic and medical laser systems, announced that it has received regulatory clearance from the U.S. FDA (Food and Drug Administration) for the eCO2 system.